https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/731243 Thu, 21 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731243-nextgen-bioscience-reports-new-s1p1-and-s1p4-receptor-antagonists http://www.bioworld.com/articles/731235 Thu, 21 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731235-recludix-presents-stat1-3-inhibitors-for-dermatological-diseases Skin irritation on hands http://www.bioworld.com/articles/731233 Thu, 21 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731233-fda-clears-qihan-biotechs-car-t-therapy-qt-019c-for-clinic Illustration of CAR T cell therapy in rheumatoid arthritis http://www.bioworld.com/articles/731339 Wed, 20 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731339-immunovant-rises-on-imvt-1402-data-in-difficult-to-treat-ra Hands highlighted with joint pain http://www.bioworld.com/articles/731177 Wed, 20 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731177-genescience-presents-stat6-degrader-for-atopic-dermatitis http://www.bioworld.com/articles/731176 Wed, 20 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731176-re-aim-therapeutics-launches-with-focus-on-autoimmune-diseases Syringe, vial with pound currency symbol http://www.bioworld.com/articles/731363 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731363-degron-closes-40m-series-a-to-advance-molecular-glue-degraders Green molecules http://www.bioworld.com/articles/731326 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731326-create-medicines-secures-122m-for-in-vivo-cars Black dollar sign on ombre blue background http://www.bioworld.com/articles/731316 Mon, 18 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731316-degron-closes-40m-series-a-to-advance-molecular-glue-degraders Green molecules http://www.bioworld.com/articles/731122 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731122-financing-at-create-medicines-to-advance-in-vivo-car-therapies Dollar sign dropper and test tube http://www.bioworld.com/articles/731119 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731119-asgct-2026-directed-evolution-in-gene-therapy DNA and genome editing illustration http://www.bioworld.com/articles/731267 Thu, 14 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731267-advancing-the-best-of-both-bms-hengrui-enter-152b-deal Test tubes, dropper and capsules http://www.bioworld.com/articles/731101 Thu, 14 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731101-epiriums-15-pgdh-inhibitor-ibd-candidates-improve-disease-outcomes-in-models Intestine http://www.bioworld.com/articles/731268 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731268-asgct-2026-circular-rna-the-new-beast-in-gene-and-cell-therapy Illustration of a glowing circle to represent circRNA http://www.bioworld.com/articles/731077 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731077-boehringer-ingelheim-licenses-immunitas-antibody-program 3D illustration antibody http://www.bioworld.com/articles/731074 Wed, 13 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731074-aop-health-and-vrg-therapeutics-partner-on-immunology-program Scientist, microscope and dropper http://www.bioworld.com/articles/731047 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731047-advancing-the-best-of-both-bms-hengrui-enter-152b-deal Test tubes, dropper and capsules http://www.bioworld.com/articles/731155 Mon, 11 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731155-in-vivo-mrna-gene-therapy-platform-reprograms-cytotoxic-t-cells Gray and red T cell http://www.bioworld.com/articles/731006 Mon, 11 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731006-shanghai-jeyou-pharmaceutical-patents-lgals3-inhibitors http://www.bioworld.com/articles/730983 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730983-in-vivo-mrna-gene-therapy-platform-reprograms-cytotoxic-t-cells Gray and red T cell http://www.bioworld.com/articles/730980 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730980-odysseys-ipo-placement-brings-304m-to-lead-drugs-in-ibd-lupus IPO, coins, financial chart http://www.bioworld.com/articles/730979 Fri, 08 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730979-budo-judo-moves-aplenty-for-climb-in-autoimmune Illustration of antibodies attacking nerve cells http://www.bioworld.com/articles/730952 Fri, 08 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730952-hepatitis-a-vaccine-nonclinical-efficacy-can-be-tested-in-ifn-receptor-ko-mice Illustration of liver infection http://www.bioworld.com/articles/730949 Fri, 08 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730949-seed-financing-at-parcelbio-to-advance-mrna-medicines Illustration of messenger RNA http://www.bioworld.com/articles/730972 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730972-atara-rises-on-new-fda-pathway-for-ebvallo-resubmission http://www.bioworld.com/articles/730929 Thu, 07 May 2026 11:00:00 -0400 https://www.bioworld.com/articles/730929-first-measles-treatment-advances-as-vaccination-rates-drop Rendering of a key measles protein targeted by neutralizing human antibodies This rendering shows a key measles protein (white) targeted by neutralizing human antibodies (pink). Credit: Dawid Zyla, La Jolla Institute for Immunology http://www.bioworld.com/articles/730923 Tue, 05 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730923-ucb-onboards-more-autoimmune-tces-with-22b-candid-buy T cells H)-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors. As such, they are described as potentially useful for the treatment of autoimmune, cardiovascular disease, inflammatory disorders, multiple sclerosis, psoriasis, gout, obesity, and sepsis, among others.]]> http://www.bioworld.com/articles/730892 Tue, 05 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730892-deepcure-develops-new-brd4-bd2-inhibitors http://www.bioworld.com/articles/730882 Tue, 05 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730882-evotec-and-almirall-derm-alliance-yields-development-candidate Illustration showing skin anatomy Rimqarto (anbalcabtagene-autoleucel; anbal-cel) April 29 as the first homegrown CAR T-cell therapy to treat patients with advanced diffuse large B-cell lymphomas.]]> http://www.bioworld.com/articles/730928 Tue, 05 May 2026 08:00:00 -0400 https://www.bioworld.com/articles/730928-mfds-clears-curocells-anbal-cel-as-first-homegrown-car-t-therapy Green approved stamp